{"id":8013,"date":"2022-06-12T09:37:25","date_gmt":"2022-06-12T17:37:25","guid":{"rendered":"https:\/\/store.apotheraspecialtypharmacy.com\/?p=8013"},"modified":"2023-05-10T18:08:07","modified_gmt":"2023-05-11T02:08:07","slug":"fda-approves-fylnetra-pegfilgrastim-pbbk-biosimilar-to-neulasta-pegfilgrastim","status":"publish","type":"post","link":"https:\/\/store.apotheraspecialtypharmacy.com\/?p=8013","title":{"rendered":"FDA Approves Fylnetra (pegfilgrastim-pbbk), Biosimilar to Neulasta (pegfilgrastim), for Treating Neutropenia"},"content":{"rendered":"<p>Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (\u201cAmneal\u201d or the \u201cCompany\u201d) today announced that the U.S. Food and Drug Administration (\u201cFDA\u201d) has approved the Company\u2019s Biologics License Application (\u201cBLA\u201d) for pegfilgrastim-pbbk, a biosimilar referencing Neulasta<sup>\u00ae<\/sup>. The product will be marketed under the proprietary name FYLNETRA\u2122.<\/p>\n<p>FYLNETRA was developed in collaboration with Kashiv Biosciences, LLC, located in Chicago, Illinois. It is used to treat neutropenia (low neutrophils which are a type of white blood cells that fight infection) which is commonly experienced by patients undergoing chemotherapy.<\/p>\n<p>This marks the third biosimilar approval Amneal received this year for products used in oncology, the second-largest biosimilar category in the U.S. Earlier this year, Amneal received approval of Releuko<sup>\u00ae\u00a0<\/sup>(filgrastim-ayow), a filgrastim biosimilar referencing Neupogen<sup>\u00ae<\/sup>, and Alymsys<sup>\u00ae<\/sup>\u00a0(bevacizumab-maly), a bevacizumab biosimilar referencing Avastin<sup>\u00ae<\/sup>. Amneal expects to launch these three products over the second half of 2022, along with a full patient support program.<\/p>\n<p><b>Indications:\u00a0<\/b>FYLNETRA is a leukocyte growth factor indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.<\/p>\n<p><b>Limitations of Use<\/b>: FYLNETRA is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.<\/p>\n<p><b>FYLNETRA IMPORTANT SAFETY INFORMATION<\/b><\/p>\n<p>FYLENTRA is contraindicated in patients with a history of serious allergic reactions to human granulocyte colony-stimulating factors such as filgrastim products or pegfilgrastim products.<\/p>\n<p>Before you take FYLNETRA, tell your healthcare provider if you are pregnant or plan to breast feed, and if you have sickle cell disorder, kidney problems or receiving radiation therapy.<\/p>\n<p><b>WARNINGS AND PRECAUTIONS<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>Fatal splenic rupture: Patients may experience enlarged spleen which can rupture and cause death.<\/li>\n<li>Acute respiratory distress syndrome (ARDS): Patients may develop fever and lung infiltrates or respiratory distress. Discontinue FYLNETRA in patients with ARDS.<\/li>\n<li>Fatal sickle cell crises: Serious sickle cell crises have been reported in patients with sickle cell disorders receiving FYLNETRA. Discontinue FYLNETRA if sickle cell crisis occurs.<\/li>\n<li>Serious allergic reactions, including anaphylaxis: Permanently discontinue FYLNETRA in patients with serious allergic reactions.<\/li>\n<li>Kidney injury (Glomerulonephritis): Kidney injury have been reported in patients on FYLNETRA. Consider dose-reduction or interruption of FYLNETRA in patients with kidney injury.<\/li>\n<li>Decreased platelet count (thrombocytopenia); and increased white blood cell count (leukocytosis) have been reported. Monitor platelet counts and white blood cell count.<\/li>\n<li>Capillary leak syndrome has been reported after G-CSF administration, including pegfilgrastim products, and is characterized by hypotension, hypoalbuminemia, edema and hemoconcentration.<\/li>\n<li>The possibility that pegfilgrastim products act as a growth factor for any tumor type, including myeloid malignancies and myelodysplasia, diseases for which pegfilgrastim products are not approved, cannot be excluded.<\/li>\n<li>Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML): Monitor patients with breast and lung cancer using FYLNETRA in conjunction with chemotherapy and\/or radiotherapy for signs and symptoms of MDS\/AML.<\/li>\n<li>Aortitis has been reported in patients receiving pegfilgrastim products.<\/li>\n<li>Increased hematopoietic activity of the bone marrow in response to growth factor therapy has been associated with transient positive bone imaging changes.<\/li>\n<\/ul>\n<p><b>ADVERSE REACTIONS<\/b><\/p>\n<p>Most common adverse reactions (\u2265 5% difference in incidence compared to placebo) are bone pain and pain in extremity.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (\u201cAmneal\u201d or the \u201cCompany\u201d) today announced that the U.S. Food and Drug Administration (\u201cFDA\u201d) has approved the Company\u2019s Biologics License Application (\u201cBLA\u201d) for pegfilgrastim-pbbk, a&hellip;<\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[16],"tags":[820,518,275,822,297,816,818,824,821,819,817,823],"class_list":["post-8013","post","type-post","status-publish","format-standard","hentry","category-blog","tag-amneal-pharmaceutical","tag-apothera-clinical-decision-support","tag-cancer","tag-chemotherapy","tag-clinical-decision-support","tag-fylnetra","tag-neulasta","tag-neupogen","tag-neutropenia","tag-pegfilgrastim","tag-pegfilgrastim-pbbk","tag-releuko"],"jetpack_featured_media_url":"","jetpack-related-posts":[{"id":10056,"url":"https:\/\/store.apotheraspecialtypharmacy.com\/?p=10056","url_meta":{"origin":8013,"position":0},"title":"In Stock: Fylnetra (Pegfilgrastim-pbbk, Biosimilar to Neulasta) 6mg\/0.6mL Syringe","date":"April 1, 2023","format":false,"excerpt":"In Stock: Fylnetra 6mg\/0.6mL Neulasta Biosimilar (Click Here) Prevention of Chemotherapy-Induced Neutropenia \u2013 6 mg SC once per chemotherapy cycle, beginning at least 24 hours after completion of chemotherapy \u2013 Do not administer in the period between 14 days before and 24 hours after administration of cytotoxic chemotherapy. Find a\u2026","rel":"","context":"In &quot;Blog&quot;","img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":10896,"url":"https:\/\/store.apotheraspecialtypharmacy.com\/?p=10896","url_meta":{"origin":8013,"position":1},"title":"In Stock: Fylnetra (Pegfilgrastim-pbbk, Biosimilar to Neulasta) 6mg\/0.6mL Syringe","date":"May 1, 2023","format":false,"excerpt":"In Stock: Fylnetra (Pegfilgrastim-pbbk, Biosimilar of Neulasta) 6mg\/0.6mL Syringe (Click Here) Prevention of Chemotherapy-Induced Neutropenia \u2013 6 mg SC once per chemotherapy cycle, beginning at least 24 hours after completion of chemotherapy \u2013 Do not administer in the period between 14 days before and 24 hours after administration of cytotoxic\u2026","rel":"","context":"In &quot;Blog&quot;","img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":9979,"url":"https:\/\/store.apotheraspecialtypharmacy.com\/?p=9979","url_meta":{"origin":8013,"position":2},"title":"In Stock: Pegfilgrastim-jmdb (Fulphila, Biosimilar to Neulasta) 6mg\/0.6mL Syringe","date":"March 29, 2023","format":false,"excerpt":"In Stock: Fulphila Biosimilar to Neulasta (Pegfilgrastim-jmdb) 6mg\/0.6mL Syringe (Click Here) Prevention of Chemotherapy-Induced Neutropenia \u2013 6 mg SC once per chemotherapy cycle, beginning at least 24 hours after completion of chemotherapy \u2013 Do not administer in the period between 14 days before and 24 hours after administration of cytotoxic\u2026","rel":"","context":"In &quot;Blog&quot;","img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":10893,"url":"https:\/\/store.apotheraspecialtypharmacy.com\/?p=10893","url_meta":{"origin":8013,"position":3},"title":"In Stock: Fulphila (Pegfilgrastim-jmdb, Biosimilar of Neulasta) 6mg\/0.6mL Syringe","date":"May 1, 2023","format":false,"excerpt":"In Stock: Fulphila (Pegfilgrastim-jmdb, Biosimilar of Neulasta) 6mg\/0.6mL Syringe (Click Here) Prevention of Chemotherapy-Induced Neutropenia \u2013 6 mg SC once per chemotherapy cycle, beginning at least 24 hours after completion of chemotherapy \u2013 Do not administer in the period between 14 days before and 24 hours after administration of cytotoxic\u2026","rel":"","context":"In &quot;Blog&quot;","img":{"alt_text":"Fulphila (Pegfilgrastim-jmdb, Biosimilar of Neulasta) 6mg\/0.6mL Syringe","src":"https:\/\/i0.wp.com\/store.apotheraspecialtypharmacy.com\/wp-content\/uploads\/2023\/05\/Fulphilia.6mg.0.6mL-3.jpg?fit=521%2C292&ssl=1&resize=350%2C200","width":350,"height":200},"classes":[]},{"id":10091,"url":"https:\/\/store.apotheraspecialtypharmacy.com\/?p=10091","url_meta":{"origin":8013,"position":4},"title":"In Stock: Neulasta Biosimilar (Fulphila, Pegfilgrastim-jmdb) 6mg\/0.6mL Syringe","date":"April 2, 2023","format":false,"excerpt":"In Stock: Neulasta Biosimilar (Fulphila, Pegfilgrastim-jmdb) 6mg\/0.6mL (Click Here) Prevention of Chemotherapy-Induced Neutropenia \u2013 6 mg SC once per chemotherapy cycle, beginning at least 24 hours after completion of chemotherapy \u2013 Do not administer in the period between 14 days before and 24 hours after administration of cytotoxic chemotherapy. \u00a0\u2026","rel":"","context":"In &quot;Blog&quot;","img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":11152,"url":"https:\/\/store.apotheraspecialtypharmacy.com\/?p=11152","url_meta":{"origin":8013,"position":5},"title":"In Stock:\u00a0Pegfilgrastim\u00a0(Fylnetra, Fulphila, Neulasta, Stimufend, Udenyca, Ziextenzo) | Cancer Supportive Care | ApoThera | Irvine, Orange County, California","date":"May 11, 2023","format":false,"excerpt":"In Stock: Pegfilgrastim - Biosimilars of Neulasta (Click Here) \u2013 Rx Required \u2013 Free Overnight Shipping (CA) \u2013 No Shipping to Outside of California \u2013 Accept FSA and HSA Cards \u2013 Accept Credit Cards Prevention of Chemotherapy-Induced Neutropenia \u2013 6 mg SC once per chemotherapy cycle, beginning at least 24\u2026","rel":"","context":"In &quot;Blog&quot;","img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]}],"_links":{"self":[{"href":"https:\/\/store.apotheraspecialtypharmacy.com\/index.php?rest_route=\/wp\/v2\/posts\/8013","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/store.apotheraspecialtypharmacy.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/store.apotheraspecialtypharmacy.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/store.apotheraspecialtypharmacy.com\/index.php?rest_route=\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/store.apotheraspecialtypharmacy.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=8013"}],"version-history":[{"count":5,"href":"https:\/\/store.apotheraspecialtypharmacy.com\/index.php?rest_route=\/wp\/v2\/posts\/8013\/revisions"}],"predecessor-version":[{"id":8018,"href":"https:\/\/store.apotheraspecialtypharmacy.com\/index.php?rest_route=\/wp\/v2\/posts\/8013\/revisions\/8018"}],"wp:attachment":[{"href":"https:\/\/store.apotheraspecialtypharmacy.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=8013"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/store.apotheraspecialtypharmacy.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=8013"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/store.apotheraspecialtypharmacy.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=8013"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}